Oukangweishi Biotech announced that in June 2026, the marketing registration application for Shishu's new drug was approved by the State Drug Administration; the current dexamethasone drug registration application has been accepted by the Drug Evaluation Center of the State Drug Administration as a category 4 chemicals, and has applied for inclusion in the list of priority review varieties and completed the publicity process.

Oukangweishi Biotech announced that in June 2026, the marketing registration application for Shishu's new drug was approved by the State Drug Administration; the current dexamethasone drug registration application has been accepted by the Drug Evaluation Center of the State Drug Administration as a category 4 chemicals, and has applied for inclusion in the list of priority review varieties and completed the publicity process.